These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 30115657)

  • 1. Relationship between CD33 expression, splicing polymorphism, and
    Laszlo GS; Beddoe ME; Godwin CD; Bates OM; Gudgeon CJ; Harrington KH; Walter RB
    Haematologica; 2019 Feb; 104(2):e59-e62. PubMed ID: 30115657
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA Approval: Gemtuzumab Ozogamicin for the Treatment of Adults with Newly Diagnosed CD33-Positive Acute Myeloid Leukemia.
    Jen EY; Ko CW; Lee JE; Del Valle PL; Aydanian A; Jewell C; Norsworthy KJ; Przepiorka D; Nie L; Liu J; Sheth CM; Shapiro M; Farrell AT; Pazdur R
    Clin Cancer Res; 2018 Jul; 24(14):3242-3246. PubMed ID: 29476018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and functional characterization of CD33 transcript variants in human acute myeloid leukemia.
    Laszlo GS; Harrington KH; Gudgeon CJ; Beddoe ME; Fitzgibbon MP; Ries RE; Lamba JK; McIntosh MW; Meshinchi S; Walter RB
    Oncotarget; 2016 Jul; 7(28):43281-43294. PubMed ID: 27248327
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.
    Lamba JK; Chauhan L; Shin M; Loken MR; Pollard JA; Wang YC; Ries RE; Aplenc R; Hirsch BA; Raimondi SC; Walter RB; Bernstein ID; Gamis AS; Alonzo TA; Meshinchi S
    J Clin Oncol; 2017 Aug; 35(23):2674-2682. PubMed ID: 28644774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
    Laszlo GS; Gudgeon CJ; Harrington KH; Dell'Aringa J; Newhall KJ; Means GD; Sinclair AM; Kischel R; Frankel SR; Walter RB
    Blood; 2014 Jan; 123(4):554-61. PubMed ID: 24311721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials.
    Gale RE; Popa T; Wright M; Khan N; Freeman SD; Burnett AK; Russell NH; Hills RK; Linch DC
    Blood; 2018 Jan; 131(4):468-471. PubMed ID: 29229596
    [No Abstract]   [Full Text] [Related]  

  • 7. MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers.
    Fultang L; Panetti S; Ng M; Collins P; Graef S; Rizkalla N; Booth S; Lenton R; Noyvert B; Shannon-Lowe C; Middleton G; Mussai F; De Santo C
    EBioMedicine; 2019 Sep; 47():235-246. PubMed ID: 31462392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Broad Anti-AML Activity of the CD33/CD3 BiTE Antibody Construct, AMG 330, Is Impacted by Disease Stage and Risk.
    Harrington KH; Gudgeon CJ; Laszlo GS; Newhall KJ; Sinclair AM; Frankel SR; Kischel R; Chen G; Walter RB
    PLoS One; 2015; 10(8):e0135945. PubMed ID: 26305211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy.
    Godwin CD; Laszlo GS; Fiorenza S; Garling EE; Phi TD; Bates OM; Correnti CE; Hoffstrom BG; Lunn MC; Humbert O; Kiem HP; Turtle CJ; Walter RB
    Leukemia; 2021 Sep; 35(9):2496-2507. PubMed ID: 33589747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.
    Oya S; Ozawa H; Nakamura T; Mori A; Ochi S; Maehiro Y; Umeda M; Takaki Y; Fukuyama T; Yamasaki Y; Yamaguchi M; Aoyama K; Mouri F; Nagafuji K
    Int J Hematol; 2024 Aug; 120(2):194-202. PubMed ID: 38853211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia.
    Hoseini SS; Vadlamudi M; Espinosa-Cotton M; Tran H; Feng Y; Guo HF; Xu H; Cheung I; Cheung NV
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin.
    Lamba JK; Meshinchi S
    Haematologica; 2021 Nov; 106(11):2796-2798. PubMed ID: 34092060
    [No Abstract]   [Full Text] [Related]  

  • 13. T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330.
    Laszlo GS; Gudgeon CJ; Harrington KH; Walter RB
    Blood Cancer J; 2015 Aug; 5(8):e340. PubMed ID: 26295610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMGN779, a Novel CD33-Targeting Antibody-Drug Conjugate with DNA-Alkylating Activity, Exhibits Potent Antitumor Activity in Models of AML.
    Kovtun Y; Noordhuis P; Whiteman KR; Watkins K; Jones GE; Harvey L; Lai KC; Portwood S; Adams S; Sloss CM; Schuurhuis GJ; Ossenkoppele G; Wang ES; Pinkas J
    Mol Cancer Ther; 2018 Jun; 17(6):1271-1279. PubMed ID: 29588393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
    Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
    Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.
    Krupka C; Kufer P; Kischel R; Zugmaier G; Bögeholz J; Köhnke T; Lichtenegger FS; Schneider S; Metzeler KH; Fiegl M; Spiekermann K; Baeuerle PA; Hiddemann W; Riethmüller G; Subklewe M
    Blood; 2014 Jan; 123(3):356-65. PubMed ID: 24300852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A.
    Stanchina M; Pastore A; Devlin S; Famulare C; Stein E; Taylor J
    J Hematol Oncol; 2019 Aug; 12(1):85. PubMed ID: 31439003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin.
    Short NJ; Richard-Carpentier G; Kanagal-Shamanna R; Patel KP; Konopleva M; Papageorgiou I; Pemmaraju N; Borthakur G; Ravandi F; DiNardo CD; Kadia TM; Kantarjian H; Lamba JK; Daver N
    Am J Hematol; 2020 Sep; 95(9):E225-E228. PubMed ID: 32356320
    [No Abstract]   [Full Text] [Related]  

  • 19. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330: reversing a T-cell-induced immune escape mechanism.
    Krupka C; Kufer P; Kischel R; Zugmaier G; Lichtenegger FS; Köhnke T; Vick B; Jeremias I; Metzeler KH; Altmann T; Schneider S; Fiegl M; Spiekermann K; Bauerle PA; Hiddemann W; Riethmüller G; Subklewe M
    Leukemia; 2016 Feb; 30(2):484-91. PubMed ID: 26239198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia.
    Norsworthy KJ; Ko CW; Lee JE; Liu J; John CS; Przepiorka D; Farrell AT; Pazdur R
    Oncologist; 2018 Sep; 23(9):1103-1108. PubMed ID: 29650683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.